-
公开(公告)号：EP3609920A1
公开(公告)日：2020-02-19
申请号：EP18720834.3
申请日：2018-04-04
-
公开(公告)号：EP3107938A1
公开(公告)日：2016-12-28
申请号：EP15799575.4
申请日：2015-05-29
申请人： Zymeworks, Inc.
发明人： SANCHES, Mario , SPRETER VON KREUDENSTEIN, Thomas , UROSEV, Dunja , D'ANGELO, Igor Edmondo Paolo , TOM-YEW, Stacey A. L. , DIXIT, Surgit Bhimarao , CORPER, Adam Louis , CHOU, Yang-Chieh
IPC分类号： C07K16/46 , A61K39/395 , C07K16/00 , C12N15/13
CPC分类号： C07K16/468 , C07K16/2863 , C07K16/32 , C07K16/36 , C07K2317/24 , C07K2317/31 , C07K2317/515 , C07K2317/522 , C07K2317/55 , C07K2317/92 , C07K2317/94
摘要： The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.
-
3.发明公开
公开(公告)号：EP2635607A1
公开(公告)日：2013-09-11
申请号：EP11837370.3
申请日：2011-11-04
申请人： Zymeworks, Inc.
发明人： CABRERA, Eric Escobar , VON KREUDENSTEIN, Thomas Spreter , DIXIT, Surjit Bhimarao , LARIO, Paula Irene , POON, David Kai Yuen , D'ANGELO, Igor Edmondo Paolo
CPC分类号： C07K16/468 , C07K16/00 , C07K16/32 , C07K2317/30 , C07K2317/524 , C07K2317/526 , C07K2317/64
摘要： The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
-
公开(公告)号：EP2635607B1
公开(公告)日：2019-09-04
申请号：EP11837370.3
申请日：2011-11-04
申请人： Zymeworks Inc.
-
公开(公告)号：EP2681245B1
公开(公告)日：2018-05-09
申请号：EP12751893.4
申请日：2012-03-02
申请人： Zymeworks Inc.
IPC分类号： C07K19/00 , C07K14/47 , C07K14/485 , C07K14/605 , C07K14/76 , C07K16/00 , C07K16/18 , C07K16/30
CPC分类号： C07K14/765 , C07K14/47 , C07K14/4721 , C07K14/485 , C07K14/605 , C07K14/76 , C07K14/79 , C07K16/283 , C07K16/32 , C07K19/00 , C07K2317/622 , C07K2319/00 , C07K2319/31 , C12N9/6454 , C12Y304/21061
摘要： Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
-
公开(公告)号：EP4026850A1
公开(公告)日：2022-07-13
申请号：EP21214023.0
申请日：2015-05-29
申请人： Zymeworks Inc.
发明人： SANCHES, Mario , SPRETER VON KREUDENSTEIN, Thomas , UROSEV, Dunja , D'ANGELO, Igor Edmondo Paolo , TOM-YEW, Stacey A. L. , DIXIT, Surjit Bhimarao , CORPER, Adam Louis , CHOU, Yang-Chieh
IPC分类号： C07K16/46 , A61K39/395 , C07K16/36 , C07K16/28 , C07K16/32
摘要： The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C Hl and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.
-
公开(公告)号：EP2681245A1
公开(公告)日：2014-01-08
申请号：EP12751893.4
申请日：2012-03-02
申请人： Zymeworks, Inc.
IPC分类号： C07K19/00 , C07K14/47 , C07K14/485 , C07K14/605 , C07K14/76 , C07K16/00 , C07K16/18 , C07K16/30
CPC分类号： C07K14/765 , C07K14/47 , C07K14/4721 , C07K14/485 , C07K14/605 , C07K14/76 , C07K14/79 , C07K16/283 , C07K16/32 , C07K19/00 , C07K2317/622 , C07K2319/00 , C07K2319/31 , C12N9/6454 , C12Y304/21061
摘要： Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
